GENETIC MARKERS FOR PREDICTING PROGNOSIS OF BREAST CANCERS

这些研究的目的是开发新的遗传标记， 乳腺癌的预后。 它将：1）利用消减杂交 发现新的基因; 2）进一步评估等位基因的意义 染色体1 q23 -32缺失，首次由该项目描述，长- 在这个位点克隆一个假定的抑制基因的长期目标。 它将 还测量随机遗传基因座处等位基因丢失的频率，和/或 扩增来检验假设，即特定的 赋予肿瘤侵袭性行为的遗传改变直接 与该肿瘤中遗传畸变的总体频率成比例。 它将检查乳腺癌中异常甲基化的证据， 确定异常甲基化是否与等位基因 不稳定 对于选定的乳腺癌标本，正常细胞（ 血液或皮肤）将可从患者和父母双方获得。 在 这些情况下，将进行研究，以评估产妇的作用， 通过确定母亲的等位基因是否 优先丢失。

The goal of these studies is to develop new genetic markers for predicting prognosis of breast cancer. It will: 1) utilize subtractive hybridization to find new genes; and 2) further evaluate the significance of an allelic loss at chromosome 1q23-32, first described by this project, with the long- term goal of cloning a putative suppressor gene at this locus. It will also measure the frequency of allelic losses at random genetic loci and/or amplifications to test the hypothesis that the likelihood of a specific genetic alteration conferring aggressive tumor behavior is directly proportional to the overall frequency of genetic aberrations in that tumor. It will examine breast cancers for evidence of aberrant methylation to determine whether abnormal methylation is associated with allelic instability. For selected breast cancer specimens, normal cells (either blood or skin) will be available from the patient and both parents. In these cases, studies will be performed to evaluate the role of maternal imprinting in breast cancer by determining whether the maternal allele is preferentially lost.